Ispire Technology Expands Into High-Growth Nicotine Pouch Market Through Strategic Joint Venture with Jincheng Pharma

Rhea-AI Summary

Ispire Technology (NASDAQ: ISPR) formed a strategic joint venture with Shandong Jincheng Pharmaceutical Group to manufacture and commercialize nicotine pouch products. The deal marks Ispire’s entry into the fast-growing oral nicotine category, expanding beyond vaping hardware into a segment projected to exceed $40 billion by 2033.

Jincheng Pharma will provide manufacturing equipment, expertise, and pouch materials, while Ispire contributes precision dosing know-how, regulatory compliance, and global distribution. Initial production is expected to leverage existing commercial relationships and support Ispire’s broader international reduced-risk nicotine platform strategy.

Positive

• Strategic joint venture adds nicotine pouches to Ispire’s product portfolio
• Entry into nicotine pouch market estimated at $7 billion in 2025
• Target segment projected to grow nearly 25% annually through 2033
• Jincheng contributes manufacturing equipment, materials, and technical expertise
• Ispire leverages existing global distribution and regulatory infrastructure
• Initial production expected to be supported by existing commercial relationships

Negative

• None.

News Market Reaction – ISPR

+3.64%

1 alert

+3.64% Session close to close

$86.67M Market Cap

0.3x Rel. Volume

In the May 12 session, ISPR gained 3.64%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement expands Ispire beyond vaping hardware into nicotine pouches, a category estimated ...

Analysis

This announcement expands Ispire beyond vaping hardware into nicotine pouches, a category estimated at $7 billion in 2025 and potentially above $40 billion by 2033. The JV pairs Jincheng’s pharmaceutical manufacturing scale with Ispire’s distribution and regulatory infrastructure. In light of recent 10‑Q filings showing revenue declines and losses, investors may track how quickly this partnership translates into revenue and whether it supports the broader nicotine platform strategy.

Key Figures

Nicotine pouch market size 2025: $7 billion Projected CAGR: 25% annually Projected market size 2033: $40 billion +2 more

5 metrics

Nicotine pouch market size 2025 $7 billion Global nicotine pouch market value in 2025 (Grand View Research)

Projected CAGR 25% annually Projected annual growth rate for nicotine pouches through 2033

Projected market size 2033 $40 billion Potential global nicotine pouch market by 2033

Jincheng employees 3,800 Approximate employee count at Jincheng Pharma

Affiliated companies 30+ Number of affiliated companies at Jincheng Pharma

Historical Context

5 past events · Latest: May 07 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 07	Q3 2026 earnings	Negative	+10.1%	Weaker revenue and sizable net loss but shares rose over ten percent.
May 01	Earnings call notice	Neutral	+1.4%	Scheduled Q3 2026 earnings call and provided access details for investors.
Apr 23	Industry awards	Positive	-10.9%	IKETech won age‑assurance awards but the stock fell sharply afterward.
Apr 09	FDA engagement	Positive	-3.8%	ENGS compliance tech presented to FDA; shares declined despite the update.
Mar 16	FDA draft guidance	Positive	+11.1%	FDA recognition of device‑level age verification drove a strong double‑digit gain.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has often produced sharp but inconsistent reactions, with several positive regulatory/technology updates seeing divergent price moves, while earnings-related items have sometimes traded counter to weaker fundamentals.

Recent Company History

Over the last six months, Ispire has alternated between financial pressure and strategic/regulatory milestones. Fiscal Q3 2026 results on May 7 showed losses and lower revenue yet the stock rose 10.12%. Earlier, FDA-related age‑verification updates on Mar 16 and Apr 9 produced double‑digit and mid‑single‑digit moves in opposite directions. Awards for IKETech on Apr 23 saw a -10.86% reaction. Today’s partnership JV extends the strategic shift toward broader nicotine platforms and compliance technology.

Key Terms

precision dosing, pharmaceutical intermediates, active pharmaceutical ingredients (APIs)

3 terms

precision dosing medical

"Ispire Technology Inc. ("Ispire" ) (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing"

Precision dosing means tailoring a medication’s dose to an individual patient’s characteristics—such as age, weight, kidney function, genetics or other biomarkers—so the drug works best and causes fewer side effects. For investors, it signals a way to increase a therapy’s effectiveness, reduce costly trial failures or safety recalls, and create competitive advantage or new revenue streams through targeted approval, diagnostics, and premium pricing, much like customizing a recipe for one person’s taste instead of serving a single portion for everyone.

pharmaceutical intermediates medical

"The company is engaged in the research, development, production, and commercialization of pharmaceutical intermediates, active pharmaceutical ingredients (APIs)"

Pharmaceutical intermediates are the chemical building blocks and semi-finished ingredients used in the step-by-step manufacture of active medicines; think of them as the car parts that are assembled into a finished vehicle. They matter to investors because control of intermediate supply, quality and cost affects a drug maker’s production speed, profit margins and regulatory risk—so shortages or price changes can quickly influence company revenue and stock value.

active pharmaceutical ingredients (APIs) medical

"The company is engaged in the research, development, production, and commercialization of pharmaceutical intermediates, active pharmaceutical ingredients (APIs)"

Active pharmaceutical ingredients (APIs) are the chemical or biological substances in a medicine that produce the intended therapeutic effect — think of them as the engine inside a car that makes it run. Investors care because API supply, quality, cost, and intellectual property control determine a drug maker’s ability to sell medicines, meet regulatory requirements, and protect profit margins; disruptions or shortages can quickly affect revenue and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Partnership combines pharmaceutical-grade manufacturing with Ispire's global platform to accelerate entry into one of the fastest-growing nicotine segments

LOS ANGELES, May 12, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced that it has entered into a joint venture with Shandong Jincheng Pharmaceutical Group Co., Ltd. (SZSE: 300233) ("Jincheng Pharma"), a global pharmaceutical company, to manufacture and commercialize nicotine pouch products.

The joint venture marks Ispire's entry into the rapidly expanding oral nicotine category, broadening its portfolio beyond vaping hardware and positioning the Company in one of the fastest-growing segments of the global nicotine market. According to Grand View Research, the nicotine pouch market was approximately $7 billion in 2025 and is projected to grow at nearly 25% annually through 2033, potentially exceeding $40 billion.

"This joint venture represents a meaningful strategic expansion for Ispire," said Michael Wang, Co-Chief Executive Officer of Ispire. "Nicotine pouches are a major global growth category, and this partnership enables us to enter the market with immediate operational capability and pharmaceutical-grade manufacturing expertise. Combined with our global distribution and regulatory infrastructure, we believe this positions us to build a significant new revenue stream and further advance our broader nicotine platform strategy."

Under the terms of the agreement, Jincheng Pharma will contribute manufacturing equipment, technical expertise, and nicotine pouch materials, enabling a rapid operational ramp-up and supporting near-term production and commercialization. The joint venture is expected to leverage Ispire's strengths in precision dosing, regulatory compliance, and global distribution to differentiate its nicotine pouch offerings in an increasingly competitive market.

"Ispire's proven manufacturing excellence and global regulatory capabilities accelerate our path to commercialization," said Jiaquan Li, Chairman and President of Jincheng Pharma. "By combining our pharmaceutical expertise and customer relationships with Ispire's operational capabilities, we are well positioned to scale high-quality nicotine pouch production quickly and responsibly."

Jincheng Pharma is a diversified pharmaceutical company with approximately 3,800 employees and more than 30 affiliated companies worldwide. The company is engaged in the research, development, production, and commercialization of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), finished pharmaceutical products, and health-related products.

Jincheng selected Ispire as its partner based on Ispire's reputation for high-quality manufacturing, operational execution, and strong global regulatory compliance infrastructure.

The Company expects initial production to be supported by existing commercial relationships and intends to pursue additional business development opportunities within the oral nicotine segment as part of its broader international nicotine platform strategy.

This expansion builds on Ispire's ongoing efforts to diversify its product portfolio across multiple reduced-risk nicotine formats while leveraging its manufacturing scale, compliance capabilities, and global distribution network.

About Ispire Technology Inc.
Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company's operating subsidiaries own or license more than 400 patents worldwide. Ispire's branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People's Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company's cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company's joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the "Joint Venture") may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture's ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company's ability to collect its accounts receivable in a timely manner; the Company's business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™'s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Cautionary Note on Forward-Looking Statements" and the additional risk described in Ispire's Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

IR Contact:
Brett Maas
Hayden IR
(646) 536-7331
brett@haydenir.com 

James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com 

PR Contact:
Ellen Mellody
+1-570-209-2947
ispire@kcsa.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ispire-technology-expands-into-high-growth-nicotine-pouch-market-through-strategic-joint-venture-with-jincheng-pharma-302768974.html

SOURCE Ispire Technology Inc.

FAQ

What did Ispire Technology (NASDAQ: ISPR) announce about its nicotine pouch strategy on May 12, 2026?

Ispire Technology announced a joint venture with Jincheng Pharma to manufacture and commercialize nicotine pouch products. According to Ispire, this marks its entry into the oral nicotine category and supports its broader international reduced-risk nicotine platform strategy beyond vaping hardware.

Who is Ispire Technology’s partner in the new nicotine pouch joint venture and what will each party contribute?

Ispire’s partner is Shandong Jincheng Pharmaceutical Group. According to Ispire, Jincheng will provide manufacturing equipment, technical expertise, and nicotine pouch materials, while Ispire contributes precision dosing capabilities, regulatory compliance infrastructure, and its global distribution platform to accelerate commercialization.

How large is the nicotine pouch market Ispire (ISPR) is entering through this joint venture?

The nicotine pouch market was about $7 billion in 2025 and is projected to grow nearly 25% annually through 2033. According to Ispire, this high-growth segment could exceed $40 billion, offering a substantial opportunity for its expanded nicotine platform.

How does the Jincheng Pharma joint venture fit into Ispire Technology’s broader nicotine platform strategy?

The joint venture extends Ispire’s platform from vaping hardware into oral nicotine pouches. According to Ispire, it supports diversification across multiple reduced-risk nicotine formats while leveraging its manufacturing scale, compliance capabilities, and global distribution network to build additional international revenue streams.

What operational advantages does Ispire (ISPR) expect from its nicotine pouch joint venture with Jincheng Pharma?

Ispire expects rapid operational ramp-up using Jincheng’s equipment, expertise, and materials. According to Ispire, combining these with its precision dosing, regulatory compliance, and global distribution should help differentiate the nicotine pouch offerings and accelerate commercialization in a competitive market.

How will initial production and commercialization of Ispire’s nicotine pouch products be supported?

Initial production is expected to be supported by existing commercial relationships. According to Ispire, the company also plans to pursue additional business development opportunities within the oral nicotine segment as it scales its international reduced-risk nicotine platform.